ClinicalTrials.gg
CompletedNCT01436201Updated Oct 7, 2014Results posted

A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

A Phase 1 interventional study of Digoxin and Dulaglutide in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
51st of 54
24 · median 159
Started
2011
with 7 others
Phase 1
15 of 54
none open now
Registered
18th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 51st largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 1, and was the 18th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to study how the body processes digoxin and the effect of dulaglutide on how digoxin is processed by the body. Information about any side effects that may occur will also be collected.

This study is for research purposes only and is not intended to treat any medical condition. This research study requires that a blood sample be obtained and stored for future research involving genetic analysis.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination
  • Male participants with female partners of , or partners who are pregnant or breastfeeding, agree to use a reliable method of from the time of the first dose until 3 months after the last dose of product, as determined by the investigator. The method may be one of the following:

    • Condom with spermicidal agent
    • Male participant sterilization
    • True abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable)
  • Female participants not of child-bearing potential (that is, they are or permanently sterilized [such as, tubal occlusion, hysterectomy, bilateral salpingectomy]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrolment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or at least 1 year of spontaneous amenorrhea, with follicle stimulating hormone (FSH) ≥40 milli-international units per milliliter (mIU/mL)
  • Female participants who have undergone sterilization by tubal ligation agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrolment
  • Have a (BMI) of 18.5 to 32.0 kilogram per square meter (kg/m\^2), inclusive, at screening
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator (potassium, magnesium, and calcium values must be within the normal range)
  • Have normal renal function defined as an estimated (CrCl) of ≥80 milliliter per minute (mL/min)
  • Have venous access sufficient to allow for blood sampling
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study restrictions
  • Have given written approved by Lilly and the ethical review board (ERB) governing the site

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have known allergies to glucagon like peptide-1 (GLP-1)-related compounds including dulaglutide (LY2189265) or to digoxin, related compounds or any components of either formulation
  • Are participants who have previously completed or withdrawn from this study or any other study investigating dulaglutide in the 3 months prior to screening or have received glucagon-like peptides or incretin mimetics in the 3 months prior to screening
  • Have an abnormality in the 12-lead (ECG) (such as, first, second, or third degree atrioventricular [AV] block, prolonged [QTc] interval, sinus tachycardia, sinus bradycardia, atrial fibrillation, or sinus node disease) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a history of significant dysrhythmias or AV block
  • Have an abnormal blood pressure (after at least 5 minutes sitting) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a history or presence of cardiac, respiratory, hepatic, renal, endocrine (such as, hypothyroidism), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying (GE) (such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician
  • Show evidence of significant active neuropsychiatric disease
  • Have family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Show evidence of and/or positive hepatitis B surface antigen
  • Are women with a positive pregnancy test or women who are lactating
  • Have used or intend to use over-the-counter medication other than acetaminophen within 7 days prior to dosing or prescription medication (with the exception of vitamin/mineral supplements) within 14 days prior to dosing, or have used St John's Wort within 14 days prior to dosing
  • Have donated blood of more than 500 mL within the month prior to screening
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) 14 units per week (females), or are unwilling to stop alcohol consumption from screening through follow-up (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • Are smokers
  • Have a history of cancer with the past 20 years, with the exception of basal cell or squamous cell skin cancer, or treated cervical carcinoma in situ
  • Intend to consume grapefruit within 7 days prior to dosing
  • Are participants who, in the opinion of the investigator, are in any way unsuitable to participate in the study
  • Have any medical conditions, medical history or are taking any medication which are
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Digoxin + Dulaglutide

    Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17. Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15.

    Drug: Digoxin · Biological: Dulaglutide

Interventions

  • Administered orally

  • BiologicalDulaglutide

    Administered as subcutaneous injection

    Also known as: LY2189265

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin

    Time frame: Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17

  2. Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Digoxin

    Time frame: Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17

  3. Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin

    Time frame: Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17

07

Results

Posted Oct 7, 2014

Participant flow

Participant flow — Overall Study
MilestoneDigoxin + Dulaglutide
Started24
Received at least 1 dose of study drug24
Completed20
Not completed4
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1
Withdrew: Protocol violation1

Outcome measures

PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin
Time frame:
Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17
Reported as:
Geometric mean · nanograms times hours/milliliter
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Digoxin
nanograms times hours/milliliterDigoxin OnlyDigoxin + Dulaglutide
Day 716.8 ± 25NA ± NA
Day 10NA ± NA16.1 ± 26
Day 17 (n=20)NA ± NA16.3 ± 32
PrimaryPharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Digoxin
Time frame:
Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17
Reported as:
Geometric mean · nanograms per milliliter
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Digoxin
nanograms per milliliterDigoxin OnlyDigoxin + Dulaglutide
Day 71.71 ± 27NA ± NA
Day 10NA ± NA1.34 ± 40
Day 17 (n=20)NA ± NA1.42 ± 42
PrimaryPharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin
Time frame:
Predose (Digoxin) and up to 24 hours postdose on Days 7, 10, and 17
Reported as:
Median · hours
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin
hoursDigoxin OnlyDigoxin + Dulaglutide
Day 71.00 (0.50 to 1.50)NA (NA to NA)
Day 10NA (NA to NA)1.50 (1.00 to 6.00)
Day 17 (n=20)NA (NA to NA)1.50 (1.00 to 4.00)

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Digoxin—0/24 (0%)13/24 (54.2%)
Digoxin + Dulaglutide—0/21 (0%)16/21 (76.2%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventDigoxinDigoxin + Dulaglutide
Gastrooesophageal reflux diseaseGastrointestinal disorders1/247/21
Atrioventricular block first degreeCardiac disorders4/246/21
NauseaGastrointestinal disorders2/246/21
HeadacheNervous system disorders0/246/21
VomitingGastrointestinal disorders0/243/21
Decreased appetiteMetabolism and nutrition disorders0/243/21
PalpitationsCardiac disorders0/242/21
DiarrhoeaGastrointestinal disorders1/242/21
DyspepsiaGastrointestinal disorders0/242/21
DizzinessNervous system disorders0/242/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Digoxin + Dulaglutide
Mean43.4 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Digoxin + Dulaglutide
Female8
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Digoxin + Dulaglutide
Hispanic or Latino12
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Digoxin + Dulaglutide
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White19
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Digoxin + Dulaglutide
United States24
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daytona Beach, Florida 32117, United States
09

References and documents

Publications

  • de la Pena A, Cui X, Geiser J, Loghin C. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clin Pharmacokinet. 2017 Nov;56(11):1415-1427. doi: 10.1007/s40262-017-0531-7. PubMed 28357715 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2011
First posted
Sep 19, 2011
Start
Sep 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01436201
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
Sep 2011
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion